Acceptance of COVID-19 Vaccination and its Related Factors Among HIV/AIDS Patients in Guangxi, China: A Cross-Sectional Survey.
Abstract Background Vaccination is the most effective approach against the coronavirus disease 2019 (COVID-2019) pandemic. This study aimed to investigate acceptance and the predominant influential factors of COVID-19 vaccination among people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Methods A cross-sectional survey was carried out in five cities in Guangxi from 7 May to 1 June 2021. Questionnaires on the acceptance of COVID-19 vaccination and the influential factors were conducted among HIV/AIDS patients recruited by random cluster sampling. We performed univariate and multivariate logistic regression analysis to identify factors associated with acceptance of COVID-19 vaccination among HIV/AIDS patients. Results Of all the participants (n = 903), 72.9% (n = 658) were willing to accept the COVID-19 vaccine and there was no statistically significant difference between CD4+T cell count and willingness to vaccinate using stratified analysis (P > 0.05). The main reason for willingness to accept the COVID-19 vaccine was fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (76.0%), whereas patients who were reluctant to receive the vaccine were mainly concerned about the safety of the vaccine (54.7%) and whether it would impact anti-retroviral therapy(ART) efficacy (50.6%). The most significant factors influencing vaccination were concerns that the vaccine was unsafe in HIV patients (OR=0.082, 95%CI = 0.024–0.282) and that it would be less effective in preventing SARS-CoV-2 infection in HIV patients (OR = 0.093, 95%CI = 0.030–0.287). Other factors associated with acceptance of the COVID-19 vaccine included Zhuang ethnicity (OR=1.653, 95%CI=1.109–2.465), the highest education level of middle school and high school or above (OR=1.747, 95%CI=1.170–2.608; OR=2.492, 95%CI=1.326–4.682), unknown vaccination type (OR=0.487, 95%CI=0.305–0.776) and little vaccine influence on ART efficacy (OR=2.889, 95%CI=1.378-6.059). Conclusions Acceptance of the COVID-19 vaccination is high among HIV/AIDS patients, although some patients refused vaccination because of vaccine safety and influence on ART efficacy. More research is needed to investigate the impact of the COVID-19 vaccine on the efficacy of ART and to evaluate its effectiveness in preventing SARS-CoV-2 infection in HIV patients so that concerns about COVID-19 vaccination issues can be addressed in HIV patients..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
ResearchSquare.com - (2022) vom: 03. Jan. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Su, Jinming [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-1109933/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034946292 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034946292 | ||
| 003 | DE-627 | ||
| 005 | 20230429175756.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-1109933/v1 |2 doi | |
| 035 | |a (DE-627)XRA034946292 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-1109933/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Su, Jinming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Acceptance of COVID-19 Vaccination and its Related Factors Among HIV/AIDS Patients in Guangxi, China: A Cross-Sectional Survey. |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Vaccination is the most effective approach against the coronavirus disease 2019 (COVID-2019) pandemic. This study aimed to investigate acceptance and the predominant influential factors of COVID-19 vaccination among people living with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). Methods A cross-sectional survey was carried out in five cities in Guangxi from 7 May to 1 June 2021. Questionnaires on the acceptance of COVID-19 vaccination and the influential factors were conducted among HIV/AIDS patients recruited by random cluster sampling. We performed univariate and multivariate logistic regression analysis to identify factors associated with acceptance of COVID-19 vaccination among HIV/AIDS patients. Results Of all the participants (n = 903), 72.9% (n = 658) were willing to accept the COVID-19 vaccine and there was no statistically significant difference between CD4+T cell count and willingness to vaccinate using stratified analysis (P > 0.05). The main reason for willingness to accept the COVID-19 vaccine was fear of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (76.0%), whereas patients who were reluctant to receive the vaccine were mainly concerned about the safety of the vaccine (54.7%) and whether it would impact anti-retroviral therapy(ART) efficacy (50.6%). The most significant factors influencing vaccination were concerns that the vaccine was unsafe in HIV patients (OR=0.082, 95%CI = 0.024–0.282) and that it would be less effective in preventing SARS-CoV-2 infection in HIV patients (OR = 0.093, 95%CI = 0.030–0.287). Other factors associated with acceptance of the COVID-19 vaccine included Zhuang ethnicity (OR=1.653, 95%CI=1.109–2.465), the highest education level of middle school and high school or above (OR=1.747, 95%CI=1.170–2.608; OR=2.492, 95%CI=1.326–4.682), unknown vaccination type (OR=0.487, 95%CI=0.305–0.776) and little vaccine influence on ART efficacy (OR=2.889, 95%CI=1.378-6.059). Conclusions Acceptance of the COVID-19 vaccination is high among HIV/AIDS patients, although some patients refused vaccination because of vaccine safety and influence on ART efficacy. More research is needed to investigate the impact of the COVID-19 vaccine on the efficacy of ART and to evaluate its effectiveness in preventing SARS-CoV-2 infection in HIV patients so that concerns about COVID-19 vaccination issues can be addressed in HIV patients. | ||
| 700 | 1 | |a Jia, Zhenwei |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Fengxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Rongfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yuting |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Beibei |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Chunlin |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Tongxue |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Yinlu |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Minjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Peijiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Junjun |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Hao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2022) vom: 03. Jan. |
| 773 | 1 | 8 | |g year:2022 |g day:03 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-1109933/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 03 |c 01 | ||
| 953 | |2 045F |a 570 | ||